Development of a standardized ELISA for the determination of autoantibodies against human M-type phospholipase A2 receptor in primary membranous nephropathy-Reference-Cited by-同舟云学术

Development of a standardized ELISA for the determination of autoantibodies against human M-type phospholipase A2 receptor in primary membranous nephropathy

Published:2013-06 Issue: Volume:421 Page:213-218
ISSN:0009-8981
Container-title:Clinica Chimica Acta
language:en
Short-container-title:Clinica Chimica Acta

Author:

Dähnrich Cornelia,Komorowski Lars,Probst Christian,Seitz-Polski Barbara,Esnault Vincent,Wetzels Jack F.,Hofstra Julia M.,Hoxha Elion,Stahl Rolf A.,Lambeau Gérard,Stöcker Winfried,Schlumberger Wolfgang

Publisher

Elsevier BV

Subject

Biochemistry (medical),Clinical Biochemistry,Biochemistry,General Medicine

Reference23 articles.

1. The pathogenesis of idiopathic membranous nephropathy: a 50-year odyssey;Glassock;Am J Kidney Dis,2010

2. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy;Polanco;J Am Soc Nephrol,2010

3. Diagnosis and natural course of membranous nephropathy;Glassock;Semin Nephrol,2003

4. Validation of a predictive model of idiopathic membranous nephropathy: its clinical and research implications;Cattran;Kidney Int,1997

5. Prognostic value of risk score and urinary markers in idiopathic membranous nephropathy;van den Brand;Clin J Am Soc Nephrol,2012

Cited by 115 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combination therapy with rituximab and low dose cyclophosphamide and prednisone in membranous nephropathy;Kidney International Reports;2024-09

2. Anti–Phospholipase A2 Receptor 1 and Anti–Cysteine Rich Antibodies, Domain Recognition and Rituximab Efficacy in Membranous Nephropathy: A Prospective Cohort Study;American Journal of Kidney Diseases;2023-12

3. Mayo Clinic consensus report on membranous nephropathy: proposal for a novel classification;Kidney International;2023-12

4. Mayo Clinic Consensus Report on Membranous Nephropathy: Proposal for a Novel Classification;Mayo Clinic Proceedings;2023-11

5. Ofatumumab in Rituximab-Resistant and Rituximab-Intolerant Patients With Primary Membranous Nephropathy: A Case Series;American Journal of Kidney Diseases;2023-09